Specialty Pharmacy

Following favorable results of the ASPIRE clinical trial, Amgen acquired Onyx Pharmaceuticals for an estimated $9.7 billion.

Walgreens now the exclusive specialty pharmacy provider for select Sigma-Tau prescription drugs Adagen, Cystaran, and Matulane.

Vaccine developed by Canadian government could be mass produced within months.

A phase 2 trial reported 100% 3-year overall survival rates with frontline therapy consisting of lenalidomide, bortezomib, and dexamethasone in younger patients with multiple myeloma.

World Health Organization declaration assures drug manufacturers that there will be a market for Ebola medications.

Thomas Morrow, MD, chief medical officer at Next IT, discusses how virtual health assistants are changing how specialty pharmacies can interact with patients to improve adherence.

Philanthropic efforts could accelerate drug development and treatment.

Recent legislation helps providers identify pharmacies that maintain current good manufacturing practices.

Supply of ZMapp now gone as death toll climbs above 1000.

Specialty drugs expected to account for 40% of total prescription spending by 2016, according to Catamaran Corporation.

Several treatments for hemorrhagic fever are in different stages of development.

A multicenter study will examine whether a drug used to treat rheumatoid arthritis can improve kidney transplant patients' health.

Screening of newborn children for hepatitis C and new, more effective hepatitis C treatments may virtually eliminate the disease in the United States by 2036.

Clinical hold on Tekmira's Ebola treatment changed to partial hold by the FDA.

In a study that has the potential to change public health recommendations for breast cancer screening, researchers have validated the value of mammography in older women.

More than 90% of women in the program received timely follow-up care.

The World Health Organization will examine an unproven Ebola treatment that showed promise in 2 Americans infected with the virus.

Patients who told their employer about a multiple sclerosis diagnosis tended to have better odds of remaining employed and had a longer tenure than those who did not.

Efforts to halt the spread of Ebola continue as a Saudi Arabian man suspected of having the virus adds to the climbing death toll in West Africa.

Increasingly, sharing of information online through social media has made blinding of placebo groups in clinical trials virtually impossible. In some disease states, particularly multiple sclerosis, virtual placebo groups may offer a solution.

FDA will no longer require Genzyme to continue the Risk Evaluation and Mitigation Strategy program.

A New York man who showed symptoms of Ebola has been deemed unlikely to have the virus.

Researchers in Taiwan have found an increased risk for head and neck cancers among patients with diabetes mellitus.

Treatment with dimethyl fumarate improved or stabilized health-related quality of life scores in patients with relapse-remitting multiple sclerosis compared to placebo.

Financial hurdles delay biopharmaceutical companies from developing treatment amidst largest Ebola hemorrhagic fever outbreak in history.

QS/1 pharmacies already have access to new Signature Indicator to validate electronic prescriptions for controlled substances.

Male latex condoms are still the best strategy for reducing the spread of HIV infection.

Armada Health Care Chief Strategy Officer Thomas Cohn discusses details of the NASP and SPAARx merger and how the unified organization will help guide specialty pharmacy into the future.

The 11th annual event is scheduled to begin May 5, 2015 at the Wynn Conference Center in Las Vegas.